By consenting to a fixed number of acquirer shares as a percent of the total consideration, the target shareholders bear the risk of loss from declines in the value of acquirer stock beginning with the definitive
But he knows that it isn't in fact definitive, so he "asks" everyone to "reverently receive this teaching as definitive.
So I would like to make it very clear that neither in this article nor from the pulpit would I say that the pope's teaching about women's ordination is not definitive.
Stockholders are encouraged to read ADESA's definitive
proxy materials in their entirety as they provide, among other things, a detailed discussion of the process that led to the proposed merger and the reasons behind the Board of Directors' recommendation that stockholders vote "FOR" the approval and adoption of the merger agreement and the merger.
If a definitive
agreement is executed, the Company would plan to file a Registration Statement on Form S-4 with the Securities and Exchange Commission in connection with the business combination, and the Company would expect to mail a proxy statement to its stockholders containing information about the business combination.
In connection with proposed merger transactions involving Equity Office and EOP Operating Limited Partnership and affiliates of The Blackstone Group, Equity Office filed a definitive
proxy statement with the SEC and furnished the definitive
proxy statement to Equity Office's shareholders.
If the parties are able to execute definitive
documents for the acquisition by Beijing Med-Pharm of a majority interest in Rongheng, the transaction must also be approved by the Ministry of Commerce of the People's Republic of China.
In connection with the proposed transaction with Harbinger Capital Partners, Applica has filed a definitive
proxy statement, proxy supplements, a Schedule 14d-9 recommendation statement and amendments thereto with the SEC.
Investors and security holders are advised to read the registration statement containing a definitive
proxy statement/prospectus that will be mailed to all stockholders of record because it contains important information.
and CellStar Corporation have unanimously approved the proposed transaction set forth in the Definitive
ICOS intends to file a revised definitive
proxy statement and other documents regarding the proposed acquisition of ICOS by Lilly with the Securities and Exchange Commission (the "SEC").
There are a number of important factors that could cause actual results to differ materially from those projected, including risks associated with our ability to satisfy the conditions to closing set forth in the definitive
agreement, product commercialization, research and clinical development, regulatory approvals, manufacturing, collaboration arrangements, liquidity, competition, intellectual property claims, litigation and other risks detailed in our latest Quarterly Report on Form 10-Q and our other public filings with the Securities and Exchange Commission.